A Game Changer for Heart Health

In a groundbreaking study, inclisiran (Leqvio), an injectable treatment, has demonstrated remarkable efficacy in reducing LDL cholesterol levels for low-risk patients not currently on lipid-lowering therapies. The VICTORION-Mono trial reveals that a simple twice-yearly injection can be a lifesaver for patients hesitant or unable to tolerate statins.

Statins: A Blessing and a Curse

While statins have significantly improved outcomes for those with atherosclerotic cardiovascular disease, many patients remain skeptical about their use. Dr. R. Scott Wright from the Mayo Clinic highlights that a growing segment of the population is either hesitant or unable to take statins due to common side effects. Inclisiran emerges as a viable alternative.

Targeting the Right Group